adenine has been researched along with Malignant Melanoma in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we found that β-mangostin from seedcases of Garcinia mangostana inhibited α-melanocyte-stimulating hormone (α-MSH)-mediated melanogenesis in B16F10 melanoma cells and a three-dimensional human skin model." | 7.85 | Depigmentation of α-melanocyte-stimulating hormone-treated melanoma cells by β-mangostin is mediated by selective autophagy. ( Kim, KD; Lee, KW; Madhi, H; Oh, SS; Park, KH; Park, S; Ryu, HW; Yoo, J, 2017) |
| " In search of such a drug, we examined the efficacy of graveoline, a bioactive compound isolated from Ruta graveolens on skin melanoma A375 cells through the use of specific signaling cascades and their inhibitors." | 7.80 | Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway. ( Bishayee, K; Ghosh, S; Khuda-Bukhsh, AR, 2014) |
| "A group of 39 patients with malignant melanoma were treated with dacarbazine 1 g/m(2) i." | 7.70 | Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. ( Braybrooke, JP; Crawley, JE; Harris, AL; Houlbrook, S; O'Byrne, KJ; Propper, DJ; Shuker, DE; Stratford, IJ; Talbot, DC, 2000) |
| "2DG/rotenone failed to increase proautophagic beclin-1 and autophagic flux in melanoma cells despite the activation of AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin complex 1 (mTORC1)." | 5.62 | 3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms. ( Bosnjak, M; Harhaji-Trajkovic, L; Kosic, M; Kravic-Stevovic, T; Mircic, A; Paunovic, V; Ristic, B; Stevanovic, D; Trajkovic, V, 2021) |
| " In this study, we found that β-mangostin from seedcases of Garcinia mangostana inhibited α-melanocyte-stimulating hormone (α-MSH)-mediated melanogenesis in B16F10 melanoma cells and a three-dimensional human skin model." | 3.85 | Depigmentation of α-melanocyte-stimulating hormone-treated melanoma cells by β-mangostin is mediated by selective autophagy. ( Kim, KD; Lee, KW; Madhi, H; Oh, SS; Park, KH; Park, S; Ryu, HW; Yoo, J, 2017) |
| " In search of such a drug, we examined the efficacy of graveoline, a bioactive compound isolated from Ruta graveolens on skin melanoma A375 cells through the use of specific signaling cascades and their inhibitors." | 3.80 | Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway. ( Bishayee, K; Ghosh, S; Khuda-Bukhsh, AR, 2014) |
| "We tested 17 malignant mucosal melanomas of the head and neck for the thymine (T)-->adenine (A) missense mutation at nucleotide 1796 in the BRAF gene using direct sequencing and a newly developed assay that uses a novel primer extension method (Mutector assay)." | 3.72 | Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. ( Begum, S; Cohen, Y; Esche, C; Goldenberg, D; Lavie, O; Rosenbaum, E; Sidransky, D; Westra, WH, 2004) |
| "A group of 39 patients with malignant melanoma were treated with dacarbazine 1 g/m(2) i." | 3.70 | Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. ( Braybrooke, JP; Crawley, JE; Harris, AL; Houlbrook, S; O'Byrne, KJ; Propper, DJ; Shuker, DE; Stratford, IJ; Talbot, DC, 2000) |
| "2DG/rotenone failed to increase proautophagic beclin-1 and autophagic flux in melanoma cells despite the activation of AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin complex 1 (mTORC1)." | 1.62 | 3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms. ( Bosnjak, M; Harhaji-Trajkovic, L; Kosic, M; Kravic-Stevovic, T; Mircic, A; Paunovic, V; Ristic, B; Stevanovic, D; Trajkovic, V, 2021) |
| "The prognosis for malignant melanoma is poor; therefore, new diagnostic methods and treatment strategies are urgently needed." | 1.39 | Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells. ( Inui, M; Morita, H; Murata, T; Okumura, K; Shimizu, K; Tagawa, T, 2013) |
| "B16cOVA melanoma was implanted to TLR7 mice to evaluate the roles of stromal TLR7 on melanoma growth." | 1.37 | Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. ( Carson, DA; Chan, M; Corr, M; Cottam, HB; Daniels, GA; Hayashi, T; Norton, JT; Tawatao, RI; Wu, CC; Yao, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ren, S | 1 |
| Wang, X | 2 |
| Song, J | 1 |
| Jin, G | 1 |
| Misek, SA | 1 |
| Newbury, PA | 1 |
| Chekalin, E | 1 |
| Paithankar, S | 1 |
| Doseff, AI | 1 |
| Chen, B | 1 |
| Gallo, KA | 1 |
| Neubig, RR | 1 |
| Zhang, L | 1 |
| Ji, Z | 1 |
| Zhang, J | 1 |
| Yang, S | 1 |
| Moschos, SJ | 1 |
| Eroglu, Z | 1 |
| Khushalani, NI | 1 |
| Kendra, KL | 1 |
| Ansstas, G | 1 |
| In, GK | 1 |
| Wang, P | 1 |
| Liu, G | 1 |
| Collichio, FA | 1 |
| Googe, PB | 1 |
| Carson, CC | 1 |
| McKinnon, K | 1 |
| Wang, HH | 1 |
| Nikolaishvilli-Feinberg, N | 1 |
| Ivanova, A | 1 |
| Arrowood, CC | 1 |
| Garrett-Mead, N | 1 |
| Conway, KC | 1 |
| Edmiston, SN | 1 |
| Ollila, DW | 1 |
| Serody, JS | 1 |
| Thomas, NE | 1 |
| Ivy, SP | 1 |
| Agrawal, L | 1 |
| Dees, EC | 1 |
| Abbruzzese, JL | 1 |
| Kosic, M | 1 |
| Paunovic, V | 1 |
| Ristic, B | 1 |
| Mircic, A | 1 |
| Bosnjak, M | 1 |
| Stevanovic, D | 1 |
| Kravic-Stevovic, T | 1 |
| Trajkovic, V | 1 |
| Harhaji-Trajkovic, L | 1 |
| Misra, SK | 1 |
| Kampert, TL | 1 |
| Pan, D | 1 |
| Sinik, L | 1 |
| Minson, KA | 1 |
| Tentler, JJ | 1 |
| Carrico, J | 1 |
| Bagby, SM | 1 |
| Robinson, WA | 1 |
| Kami, R | 1 |
| Burstyn-Cohen, T | 1 |
| Eckhardt, SG | 1 |
| Frye, SV | 1 |
| Earp, HS | 1 |
| DeRyckere, D | 1 |
| Graham, DK | 1 |
| Del Bello, B | 1 |
| Toscano, M | 1 |
| Moretti, D | 1 |
| Maellaro, E | 1 |
| Ghosh, S | 1 |
| Bishayee, K | 1 |
| Khuda-Bukhsh, AR | 1 |
| Hiramoto, K | 1 |
| Murata, T | 2 |
| Shimizu, K | 2 |
| Morita, H | 2 |
| Inui, M | 2 |
| Manganiello, VC | 1 |
| Tagawa, T | 2 |
| Arai, N | 1 |
| Lee, KW | 1 |
| Ryu, HW | 1 |
| Oh, SS | 1 |
| Park, S | 1 |
| Madhi, H | 1 |
| Yoo, J | 1 |
| Park, KH | 1 |
| Kim, KD | 1 |
| Hayashi, T | 1 |
| Chan, M | 1 |
| Norton, JT | 1 |
| Wu, CC | 1 |
| Yao, S | 1 |
| Cottam, HB | 1 |
| Tawatao, RI | 1 |
| Corr, M | 1 |
| Carson, DA | 1 |
| Daniels, GA | 1 |
| Martin, L | 1 |
| Jiang, YY | 1 |
| Yang, R | 1 |
| Wang, HJ | 1 |
| Huang, H | 1 |
| Wu, D | 1 |
| Tashiro, S | 1 |
| Onodera, S | 1 |
| Ikejima, T | 1 |
| Hammerová, J | 1 |
| Uldrijan, S | 1 |
| Táborská, E | 1 |
| Vaculová, AH | 1 |
| Slaninová, I | 1 |
| Okumura, K | 1 |
| Cohen, Y | 1 |
| Rosenbaum, E | 1 |
| Begum, S | 1 |
| Goldenberg, D | 1 |
| Esche, C | 1 |
| Lavie, O | 1 |
| Sidransky, D | 1 |
| Westra, WH | 1 |
| Berrahmoune, H | 1 |
| Herbeth, B | 1 |
| Lamont, JV | 1 |
| Masson, C | 1 |
| FitzGerald, SP | 1 |
| Visvikis-Siest, S | 1 |
| Imperatori, L | 1 |
| Damia, G | 1 |
| Taverna, P | 1 |
| Garattini, E | 1 |
| Citti, L | 1 |
| Boldrini, L | 1 |
| D'Incalci, M | 1 |
| Braybrooke, JP | 1 |
| Houlbrook, S | 1 |
| Crawley, JE | 1 |
| Propper, DJ | 1 |
| O'Byrne, KJ | 1 |
| Stratford, IJ | 1 |
| Harris, AL | 1 |
| Shuker, DE | 1 |
| Talbot, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance[NCT02581930] | Phase 2 | 18 participants (Actual) | Interventional | 2016-08-17 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Antitumor response defined as the sum of complete response (CR) and partial response (PR). CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm (<1 cm). PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT02581930)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Ibrutinib) | 0 |
Estimated using the Kaplan Meier method. (NCT02581930)
Timeframe: Duration of time from day 1 of treatment to death as a result of any cause, assessed up to 1 year
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 6 |
Progression free survival (PFS) is defined as the duration of time from Day 1 of treatment to time of progression (based on clinical or radiographic grounds) or death as a result of any cause, whichever occurs first. (NCT02581930)
Timeframe: 1 year
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 1.3 |
1 review available for adenine and Malignant Melanoma
| Article | Year |
|---|---|
[What's new in dermatological treatments?].
Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2010 |
1 trial available for adenine and Malignant Melanoma
| Article | Year |
|---|---|
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Humans; Interleukin-2; Male; Melanoma; Melanoma, Cu | 2021 |
18 other studies available for adenine and Malignant Melanoma
| Article | Year |
|---|---|
Discovery of novel ibrutinib analogues to treat malignant melanoma.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell P | 2021 |
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; D | 2022 |
Photodynamic therapy enhances skin cancer chemotherapy effects through autophagy regulation.
Topics: Adenine; Aminolevulinic Acid; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferat | 2019 |
3-Methyladenine prevents energy stress-induced necrotic death of melanoma cells through autophagy-independent mechanisms.
Topics: Adenine; AMP-Activated Protein Kinases; Animals; Autophagy; Cell Death; Deoxyglucose; JNK Mitogen-Ac | 2021 |
Nano-Assembly of Pamitoyl-Bioconjugated Coenzyme-A for Combinatorial Chemo-Biologics in Transcriptional Therapy.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Coenzyme A; Drug Carriers; Humans; Melanoma; Nanop | 2018 |
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Topics: Adenine; Animals; Azetidines; c-Mer Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Cell Surv | 2019 |
Cisplatin-induced apoptosis inhibits autophagy, which acts as a pro-survival mechanism in human melanoma cells.
Topics: Adaptor Proteins, Vesicular Transport; Adenine; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2013 |
Graveoline isolated from ethanolic extract of Ruta graveolens triggers apoptosis and autophagy in skin melanoma cells: a novel apoptosis-independent autophagic signaling pathway.
Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Humans; Me | 2014 |
Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenine; Cell Line, Tumor; Cell Movement; Cell Proliferation | 2014 |
Depigmentation of α-melanocyte-stimulating hormone-treated melanoma cells by β-mangostin is mediated by selective autophagy.
Topics: Adenine; alpha-MSH; Animals; Autophagy; Cell Survival; Garcinia mangostana; Humans; Inflammation; Me | 2017 |
Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
Topics: Adenine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Synergism; Female; Flow C | 2011 |
Mechanism of autophagy induction and role of autophagy in antagonizing mitomycin C-induced cell apoptosis in silibinin treated human melanoma A375-S2 cells.
Topics: Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Down-Regulation; Humans; Melanoma; Mitomycin; NF-ka | 2011 |
Necroptosis modulated by autophagy is a predominant form of melanoma cell death induced by sanguilutine.
Topics: Adenine; Antineoplastic Agents; Autophagy; Benzophenanthridines; Caspases; Cell Line, Tumor; Cell Su | 2012 |
Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells.
Topics: Adenine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Typ | 2013 |
Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
Topics: Adenine; DNA; Exons; Head and Neck Neoplasms; Humans; Melanocytes; Melanoma; Models, Genetic; Mutage | 2004 |
Lack of association between EGF 61A>G polymorphism and plasma EGF concentration in the STANISLAS family study.
Topics: Adenine; Epidermal Growth Factor; Guanine; Humans; Melanoma; Osmolar Concentration; Polymorphism, Ge | 2007 |
3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents.
Topics: 3T3 Cells; Adenine; Alkylating Agents; Animals; Drug Resistance; Escherichia coli; Gene Expression R | 1994 |
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.
Topics: Adenine; Adult; Aged; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Damage; Femal | 2000 |